Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for refractory non-infectious non-anterior uveitis
2024-513802-77-00Phase 3Completed
- Sponsor
- Rouen University Hospital
- Start
- Aug 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of baricitinib in noninfectious uveitis (NIU), sponsored by Rouen University Hospital. Primary endpoint: Partial remission at 6 months. Started Aug 2023; status: completed.
02
Drugs
baricitinib
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on 2024-513802-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513802-77-00.